Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shan Lin

Ophthalmology San Francisco, CA Medical Doctor

NPI 1730131236 CMS profile 123348

400 Parnassus Ave, San Francisco, CA 94143

Open in the dashboard

General payments

$374,003

301 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shan Lin of San Francisco, CA is reported in the CMS Open Payments database as having received $374,003 across 301 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,662 25
2024 General $32,847 48
2023 General $26,271 39
2022 General $89,139 53
2021 General $49,630 24
2020 General $56,958 21
2019 General $106,495 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shan Lin
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Shan Lin were reported at $12,662. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Shan Lin Ophthalmology median Middle half National median
2019 $106,495 $258 $104–$655 $163
2020 $56,958 $126 $45–$321 $114
2021 $49,630 $205 $76–$534 $132
2022 $89,139 $266 $100–$678 $149
2023 $26,271 $308 $117–$745 $160
2024 $32,847 $340 $127–$846 $164
2025 $12,662 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Iridex Corporation $149,525 29 payments
  2. Aerie Pharmaceuticals, Inc. $129,278 71 payments
  3. Alcon Vision LLC $38,272 64 payments
  4. Bausch & Lomb Americas Inc. $28,187 39 payments
  5. Allergan Inc. $13,322 18 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $10,102 22 payments
  7. Dompe US, Inc. $2,379 3 payments
  8. New World Medical,Inc. $865 8 payments
  9. Carl Zeiss Meditec USA, Inc. $526 2 payments
  10. Sight Sciences, Inc. $461 14 payments
  11. Other $1,085 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $227,058 44 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $82,195 16 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $25,088 9 payments
  4. Travel and Lodging $19,733 47 payments
  5. Food and Beverage $9,979 178 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,850 5 payments
  7. Honoraria $2,600 1 payment
  8. Long term medical supply or device loan $501 1 payment
Products named General payments · program years 2019–2025
  1. rhopressa Glaucoma $89,318 46 payments
  2. rocklatan Glaucoma $89,318 46 payments
  3. Rocklatan Glaucoma $44,477 39 payments
  4. VYZULTA $37,766 55 payments
  5. Rhopressa Glaucoma $34,771 25 payments
  6. OXERVATE $2,379 3 payments
  7. HYDRUS Microstent $971 16 payments
  8. Ahmed Glaucoma Valve $705 6 payments
  9. Kahook Dual Blade $705 6 payments
  10. Clearpath $682 4 payments
  11. Other $4,214 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record